CD72 Regulates the Growth of KIT-mutated Leukemia Cell Line Kasumi-1

Overview

Journal Sci Rep

Specialty Science

Date 2014 Apr 10

PMID 24713856

Citations 6

Authors

Tatsuki R Kataoka

Atsushi Kumanogoh

Masahiro Hirata

Koki Moriyoshi

Chiyuki Ueshima

Masahiro Kawahara

Tatsuaki Tsuruyama

Hironori Haga

Affiliations

Soon will be listed here.

Abstract

Gain-of-function mutations in KIT, a member of the receptor type tyrosine kinases, are observed in certain neoplasms, including mast cell tumors (MCTs) and acute myelogenous leukemias (AMLs). A MCT line HMC1.2 harboring the KIT mutation was reported to express CD72, which could suppress the cell proliferation. Here, we examined the ability of CD72 to modify the growth of AMLs harboring gain-of-function KIT mutations. CD72 was expressed on the surface of the AML cell line, Kasumi-1. CD72 ligation by an agonistic antibody BU40 or by a natural ligand CD100, suppressed the proliferation of the Kasumi-1 cells and enhanced cell death, as monitored by caspase-3 cleavage. These responses were associated with the phosphorylation of CD72, the formation of the CD72 - SHP-1 complex and dephosphorylation of src family kinases and JNK. Thus, these results seemed to suggest that CD72 was the therapeutic potential for AML, as is the case of MCTs.

Citing Articles

BRD9 inhibition promotes PUMA-dependent apoptosis and augments the effect of imatinib in gastrointestinal stromal tumors.

Mu J, Sun X, Zhao Z, Sun H, Sun P Cell Death Dis. 2021; 12(11):962.

PMID: 34667163 PMC: 8526701. DOI: 10.1038/s41419-021-04186-6.

Prognostic Prediction of Cytogenetically Normal Acute Myeloid Leukemia Based on a Gene Expression Model.

Yang L, Zhang H, Yang X, Lu T, Ma S, Cheng H Front Oncol. 2021; 11:659201.

PMID: 34123815 PMC: 8190396. DOI: 10.3389/fonc.2021.659201.

Semaphorins and Their Receptors in Hematological Malignancies.

Wei L, Li H, Tamagnone L, You H Front Oncol. 2019; 9:382.

PMID: 31143707 PMC: 6521731. DOI: 10.3389/fonc.2019.00382.

The Role of Semaphorin 4D in Bone Remodeling and Cancer Metastasis.

Lontos K, Adamik J, Tsagianni A, Galson D, Chirgwin J, Suvannasankha A Front Endocrinol (Lausanne). 2018; 9:322.

PMID: 29971044 PMC: 6018527. DOI: 10.3389/fendo.2018.00322.

Killer cell immunoglobulin-like receptor 2DL4 is expressed in and suppresses the cell growth of Langerhans cell histiocytosis.

Takei Y, Ueshima C, Kataoka T, Hirata M, Sugimoto A, Rokutan-Kurata M Oncotarget. 2017; 8(23):36964-36972.

PMID: 28445138 PMC: 5514884. DOI: 10.18632/oncotarget.16936.

References

Beghini A, Bellini M, Magnani I, Colapietro P, Cairoli R, Morra E . STI 571 inhibition effect on KITAsn822Lys-mediated signal transduction cascade. Exp Hematol. 2005; 33(6):682-8. DOI: 10.1016/j.exphem.2005.03.007. View

Wang L, Zhao W, Yan J, Liu P, Sun H, Zhou G . Eriocalyxin B induces apoptosis of t(8;21) leukemia cells through NF-kappaB and MAPK signaling pathways and triggers degradation of AML1-ETO oncoprotein in a caspase-3-dependent manner. Cell Death Differ. 2006; 14(2):306-17. DOI: 10.1038/sj.cdd.4401996. View

Larizza L, Magnani I, Beghini A . The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia. Leuk Lymphoma. 2004; 46(2):247-55. DOI: 10.1080/10428190400007565. View

Adachi T, Flaswinkel H, Yakura H, Reth M, Tsubata T . The B cell surface protein CD72 recruits the tyrosine phosphatase SHP-1 upon tyrosine phosphorylation. J Immunol. 1998; 160(10):4662-5. View

Jensen B, Akin C, Gilfillan A . Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders. Br J Pharmacol. 2008; 154(8):1572-82. PMC: 2518463. DOI: 10.1038/bjp.2008.204. View

Gari M, Goodeve A, Wilson G, Winship P, Langabeer S, Linch D . c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. Br J Haematol. 1999; 105(4):894-900. DOI: 10.1046/j.1365-2141.1999.01449.x. View

Ishida I, Kumanogoh A, Suzuki K, Akahani S, Noda K, Kikutani H . Involvement of CD100, a lymphocyte semaphorin, in the activation of the human immune system via CD72: implications for the regulation of immune and inflammatory responses. Int Immunol. 2003; 15(8):1027-34. DOI: 10.1093/intimm/dxg098. View

Gilfillan A, Tkaczyk C . Integrated signalling pathways for mast-cell activation. Nat Rev Immunol. 2006; 6(3):218-30. DOI: 10.1038/nri1782. View

Beghini A, Magnani I, Ripamonti C, Larizza L . Amplification of a novel c-Kit activating mutation Asn(822)-Lys in the Kasumi-1 cell line: a t(8;21)-Kit mutant model for acute myeloid leukemia. Hematol J. 2002; 3(3):157-63. DOI: 10.1038/sj.thj.6200168. View

10.

Care R, Valk P, Goodeve A, Abu-Duhier F, Geertsma-Kleinekoort W, Wilson G . Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol. 2003; 121(5):775-7. DOI: 10.1046/j.1365-2141.2003.04362.x. View

11.

Asou H, Tashiro S, Hamamoto K, Otsuji A, Kita K, Kamada N . Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood. 1991; 77(9):2031-6. View

12.

Kitamura Y, Hirotab S . Kit as a human oncogenic tyrosine kinase. Cell Mol Life Sci. 2004; 61(23):2924-31. DOI: 10.1007/s00018-004-4273-y. View

13.

Kumanogoh A, Kikutani H . The CD100-CD72 interaction: a novel mechanism of immune regulation. Trends Immunol. 2001; 22(12):670-6. DOI: 10.1016/s1471-4906(01)02087-7. View

14.

Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S . Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998; 279(5350):577-80. DOI: 10.1126/science.279.5350.577. View

15.

Barrett A, Le Blanc K . Immunotherapy prospects for acute myeloid leukaemia. Clin Exp Immunol. 2010; 161(2):223-32. PMC: 2909404. DOI: 10.1111/j.1365-2249.2010.04197.x. View

16.

Kumanogoh A, Watanabe C, Lee I, Wang X, Shi W, Araki H . Identification of CD72 as a lymphocyte receptor for the class IV semaphorin CD100: a novel mechanism for regulating B cell signaling. Immunity. 2000; 13(5):621-31. DOI: 10.1016/s1074-7613(00)00062-5. View

17.

Wu Y, Nadler M, Brennan L, Gish G, Timms J, Fusaki N . The B-cell transmembrane protein CD72 binds to and is an in vivo substrate of the protein tyrosine phosphatase SHP-1. Curr Biol. 1998; 8(18):1009-17. DOI: 10.1016/s0960-9822(07)00421-6. View

18.

Muller A, Duque J, Shizuru J, Lubbert M . Complementing mutations in core binding factor leukemias: from mouse models to clinical applications. Oncogene. 2008; 27(44):5759-73. DOI: 10.1038/onc.2008.196. View

19.

Fujiwara N, Fusaki N, Hozumi N . CD72 stimulation modulates anti-IgM induced apoptotic signaling through the pathway of NF-kappaB, c-Myc and p27(Kip1). Microbiol Immunol. 2004; 48(1):59-66. DOI: 10.1111/j.1348-0421.2004.tb03488.x. View

20.

Rovida E, Gozzini A, Barbetti V, Giuntoli S, Santini V, Dello Sbarba P . The c-Jun-N-terminal-Kinase inhibitor SP600125 enhances the butyrate derivative D1-induced apoptosis via caspase 8 activation in Kasumi 1 t(8;21) acute myeloid leukaemia cells. Br J Haematol. 2006; 135(5):653-9. DOI: 10.1111/j.1365-2141.2006.06365.x. View